Study: RAGE: Ruptured Aneurysms Treated with Hydrogel Coils. A registry study of hydrogel coils used to treat aneurysms.
Clinical Trial #: NCT03252314
Principal Investigator: Harish N. Shownkeen, MD
Contact: Kathy Kansen, RN, Clinical Research Coordinator 630.933.3317

Study: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
Clinical Trial #: NRG-BN001
NCT #: NCT02179086
Principal Investigator: Vinai Gondi, MD¹
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov

Study: A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to intermediate Grade Gliomas.
Clinical Trial #: NRG-BN005
NCT #: NCT03180502
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov

Study: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Clinical Trial #: NRG-CC003
NCT #: NCT02635009
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov

Study: A Phase II, single arm, open label trial combining Optune with concurrent Bevacizumab or Progressive Meningioma
Clinical Trial #: NU16C02
NCT #: NCT02847559
Principal Investigator: Dr. Grimm
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov

Study: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide vs. Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Clinical Trial #: N0577 (CODEL)
NCT #: NCT00887146
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov

Study: A Phase III< Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy.
Clinical Trial #: Orbus, STELLAR Study OT-15-001
NCT #: NCT02796261
Principal Investigator: Dr. Grimm
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov

Study: Pivotal, open label, randomized study of radiosurgery with or without Tumor Treating Fields for 1-10 brain metastases from non-small cell lung cancer.
Clinical Trial #: NovoCure METIS EF-25
NCT #: NCT02831959
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov

Study: Molecular Analysis for Therapy Choice (MATCH) for Patients with histologically documented solid tumors and lymphomas
Clinical Trial #: EAY131
NCT #: NCT02465060
Principal Investigator: Dr. Kahn
Contact: Kelly Schaffer, Study Coordinator 630.352.5450

Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Clinical Trial #: S1609
NCT #: NCT02834013
Principal Investigator: Dr. George
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov

Study: Serum Lactate: a potential biomarker for malignant primary brain tumors and differentiator for tumor recurrence vs. radiation necrosis
Clinical Trial #: 17-049
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450

Study: Nervous System Tumor Bank
Clinical Trial #: 17-048
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450

Study: Cerebrovascular Tumor Bank
Clinical Trial #: 17-063
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450

Study: Detection of altered cognition in brain disease via assessment of speech abnormalities as assessed by novel verbal linguistic analysis software.
Clinical Trial #: 18-046
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450

Study: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Clinical Trial #: NRG-BN003
NCT #: NCT03180268
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov

Study: New Ideas: New IDEAS will evaluate the association between amyloid PET and patient-centered outcomes in an expanded and more ethnoracially and clinically diverse group of Medicare participants presenting with cognitive impairment.
Clinical Trial #: NCT04426539
Principal Investigator: Dr. Z. Grujic
Contact: Seema Jain, Clinical Research Coordinator 630.933.7581

Study: CVL-865-SV-001 Realize: A randomized, double-blind, placebo-controlled parallel group, multicenter trial of CVL-865 as adjunctive therapy in adults with drug resistant focal onset seizures.
Clinical Trial #: NCT04244175
Principal Investigator: Dr. Sucholeiki
Contact: Seema Jain, Study Coordinator 630.933.7581

Study: CVL-865-SV-002: A 57-Week, Multicenter, Active-treatment, Open-label Extension Trial of CVL-865 as Adjunctive Therapy in Adults With Drug-Resistant Focal Onset Seizure
Clinical Trial #: NCT04686786 Enrollment by invitation only
Principal Investigator: Dr. R. Sucholeiki
Contact: Seema Jain, Clinical Research Coordinator 630.933.7581

A Humanitarian Use Device (HUD) is intended for use in patients with conditions that affect less than 4,000 people in the United States and there is no comparable device marketed to treat/diagnose those conditions or diseases. Since the number of patients is so small, the Food and Drug Administration (FDA) has approved the use of HUDs for the clinical treatment of patients without the same amount of testing that other products get. The ability of this device to treat your condition has not been proven, but the FDA believes that these devices are likely to be safe and will probably benefit patients.

Aneurysm

Study: Neuroform: Microdelivery Stent System
Treatment: The Neuroform stent can be placed in a brain artery across the opening of an aneurysm. After the stent is in place, the aneurysm sac can be filled with small metal coils. The coils prevent blood from flowing into the aneurysm and could greatly reduce the risk of aneurysm rupture. The Neuroform stent is a small metallic mesh tube that is designed to keep the coils in the aneurysm sac.
Principal Investigator: Harish N. Shownkeen, MD

Learn more at FDA.gov

Aneurysm

Study: CODMAN ENTERPRISE: TM Vascular Reconstruction Device and Delivery System
Treatment: The ENTERPRISE TM Vascular Reconstruction Device and Delivery System stent can be placed in a brain artery across the opening of an aneurysm. After the stent is in place, the aneurysm sac can be filled with small metal coils. The coils prevent blood from flowing into the aneurysm and could greatly reduce the risk of aneurysm rupture. The stent is a small metallic mesh tube that is designed to keep the coils in the aneurysm sac to aid in treating your wide-neck, intracranial, saccular or fusiform aneurysms.
Principal Investigator: Harish N. Shownkeen, MD

Learn more at FDA.gov

Study: ORCHESTRA PD 0053: A double-blind, placebo-controlled, randomized, Phase 2a study with oral UCB0599 in study participants with early Parkinson’s Disease
Clinical Trial: # 2020-003265-19
Principal Investigator: Dr. M. McGraw
Contact: Kathy Hansen, BSN CNRN Study Coordinator 630.933.3317

Study: CVL-751-PD004: 58-Week Open-label Trial of Tavapadon in Parkinson’s disease (TEMPO-4 Trial)
Clinical Trial #: 2019-002952-17 Enrollment by invitation only
Principal Investigator: Dr. Jennifer Nichols
Contact: Seema Jain, Clinical Research Coordinator 630.933.7581

Study: RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa therapy
Clinical Trial #: NCT02586623
To treat patients with the following: Parkinson's Disease (PD) and neurogenic orthostatic hypotension.
Principal Investigator: Martha T. McGraw, MD
Contact: Kathy Hansen, BSN, CNRC, Study Coordinator, 630.933.6107

Learn more at Clinicaltrials.gov

Study: Tempo 1: The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early Parkinson’s Disease
Clinical Trial #: NCT4201093
Principal Investigator: Dr. Jennifer Nichols
Contact: Seema Jain, Clinical Research Coordinator 630.933.7581

Stroke

Study: Arcadia: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
Clinical Trial #: NCT03192215
Principal Investigator: Dr. Pandya
Contact: Kathy Hansen, RN, Clinical Research Coordinator 630.933.3317

Study: MOST: The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with 0.9mg/kg IV rt-PA within three hours of symptom onset.
Clinical Trial #: NCT03735979
Principal Investigator: Dr. Sachdeva
Contact: Kathy Hansen, RN, Clinical Research Coordinator 630.933.3317

Study: TESLA: Patients presenting with symptoms of acute ischemic stroke who have evidence of a moderate‐large infarct volume in the anterior circulation will be assigned to either best medical management alone (including intravenous recombinant Tissue‐Type Plasminogen Activator [IV rtPA]) or intra‐arterial treatment (IAT) with mechanical thrombectomy added to best medical management.
Clinical Trial#: NCT03805308
Principal Investigator: Dr. D. Pandya
Contact: Kathy Hansen, RN, Clinical Research Coordinator 630.933.3317

Study: FASTEST: To test the hypothesis that treatment with rFVIIa within two hours of onset in appropriately selected patients with spontaneous ICH improves outcome as measured by the modified Rankin Scale (mRS) at 180 days, as compared to placebo.
Clinical Trial #: Not yet enrolling. We need public feedback about this research proposal! Please visit the following website - nm.org/CDH-fastest - to learn more about the clinical trial and give us your thoughts on this endeavor.
Principal Investigator: Dr. S. Shownkeen
Contact: Kathy Hansen, RN, Clinical Research Coordinator 630.933.3317

Intracranial Hemorrhage

Study: Aspire: A randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and high-risk non-valvular AF (CHA2DS2-VASc score ≥ 2). Seven hundred patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months. The primary efficacy outcome is any stroke (hemorrhagic or ischemic) or death from any cause
Clinical Trial #: NCT03907046
Principal Investigator: Dr. Pandya
Contact: Kathy Hansen, RN, Clinical Research Coordinator 630.933.3317

Study: Hemostasis and Intracranial Hemorrhage: To determine the hemostatic mechanisms of hematoma expansion after intracerebral hemorrhage (ICH), leading to specific interventions that can improve patient outcomes after ICH and other bleeding conditions (e.g. neurotrauma, Subdural hematoma).
Clinical Trial #: STU00208910
Principal Investigators: Dr. A. Naidech, Dr. H. Shownkeen
Contact: Kathy Hansen, RN, Clinical Research Coordinator 630.933.3317

Study: Saturn: A Phase 3 study of statins used in patients with a lobar intracranial hemorrhage
Clinical Trial #: NCT03936361
Principal Investigators: Dr. Gutti
Contact: Kathy Hansen, RN, Clinical Research Coordinator 630.933.3317